Abbott Laboratories
NYSE:ABT
Intrinsic Value
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. [ Read More ]
The intrinsic value of one
ABT
stock under the Base Case scenario is
91.86
USD.
Compared to the current market price of 104.51 USD,
Abbott Laboratories
is
Overvalued by 12%.
Valuation History
Abbott Laboratories
Intrinsic Value History...
Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.
Fundamental Analysis
2023-Q3 Earnings Call
NEW
Artifical Intelligence Analysis
Abbott reported a solid third quarter with an adjusted earnings per share of $1.14 and revised full-year guidance to $4.42 to $4.46, reflecting confidence in the year's strong finish. The company experienced double-digit organic sales growth across all four major business segments, excluding COVID testing. Pediatric nutrition soared with a 25% increase based on U.S. market share gains, while adult nutrition grew 12% on robust demand. Established pharmaceuticals rose 11%, led by growth in cardiometabolic, women's health, and CNS pain management, including new agreements to commercialize biosimilars in emerging markets. Core lab diagnostics excluding COVID tests grew 10%, with rapid diagnostics also seeing double-digit growth. Medical devices surged nearly 15%, fueled by FreeStyle Libre's 28% increase in sales to $1.4 billion. Expected low double-digit organic sales growth, barring COVID testing sales, sets a positive tone for the remainder of the year.
Balance Sheet Decomposition
Abbott Laboratories
| Current Assets | 22.7B |
| Cash & Short-Term Investments | 7B |
| Receivables | 6.5B |
| Other Current Assets | 9.1B |
| Non-Current Assets | 49.4B |
| Long-Term Investments | 788m |
| PP&E | 9.6B |
| Intangibles | 32.6B |
| Other Non-Current Assets | 6.5B |
| Current Liabilities | 13B |
| Accounts Payable | 4B |
| Accrued Liabilities | 6.8B |
| Other Current Liabilities | 2.3B |
| Non-Current Liabilities | 21.6B |
| Long-Term Debt | 14.5B |
| Other Non-Current Liabilities | 7.1B |
ABT Profitability Score
Profitability Due Diligence
Abbott Laboratories's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Abbott Laboratories's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
ABT Solvency Score
Solvency Due Diligence
Abbott Laboratories's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Abbott Laboratories's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABT Price Targets Summary
Abbott Laboratories
According to Wall Street analysts, the average 1-year price target for
ABT
is 118.42 USD
with a low forecast of 101 USD and a high forecast of 139.65 USD.
Ownership
ABT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ABT Price
Abbott Laboratories
| Average Annual Return | 20.2% |
| Standard Deviation of Annual Returns | 15.66% |
| Max Drawdown | -35% |
| Market Capitalization | 181B USD |
| Shares Outstanding | 1 736 060 032 |
| Percentage of Shares Shorted | 0.7% |
ABT News
Last Video News
Abbott Laboratories
Last Important Events
Abbott Laboratories
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Abbott Laboratories
Company Profile
Abbott Laboratories
Country
Industry
Market Cap
Dividend Yield
Description
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The company is headquartered in Abbott Park, Illinois and currently employs 113,000 full-time employees. The firm operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
Contact
IPO
Employees
Officers
The intrinsic value of one
ABT
stock under the Base Case scenario is
91.86
USD.
Compared to the current market price of 104.51 USD,
Abbott Laboratories
is
Overvalued by 12%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
